A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(22 sites)

United States

University of Alabama at Birmingham, Birmingham, Alabama

Yale New Haven Hospital-Smilow Cancer Center, New Haven, Connecticut

Hackensack University Medical Center, Hackensack, New Jersey

University of Texas MD Anderson Cancer Center, Houston, Texas

Canada

Arthur J E Child Comprehensive Cancer Centre, Calgary, Alberta